US 12,168,680 B2
Fusion molecules and IL-15 variants
Hing C. Wong, Culver City, CA (US); Peter Rhode, Culver City, CA (US); Xiaoyun Zhu, Culver City, CA (US); and Kai-Ping Han, Culver City, CA (US)
Assigned to Altor Bioscience, LLC, Culver City, CA (US)
Filed by Altor BioScience LLC, Culver City, CA (US)
Filed on Apr. 24, 2023, as Appl. No. 18/305,965.
Application 18/305,965 is a continuation of application No. 17/716,986, filed on Apr. 8, 2022, granted, now 11,673,932.
Application 17/716,986 is a continuation of application No. 16/654,958, filed on Oct. 16, 2019, granted, now 11,365,231, issued on Jun. 21, 2022.
Application 16/654,958 is a continuation of application No. 15/254,713, filed on Sep. 1, 2016, granted, now 10,450,359, issued on Oct. 22, 2019.
Application 15/254,713 is a continuation of application No. 13/946,438, filed on Jul. 19, 2013, granted, now 9,464,127, issued on Oct. 11, 2016.
Application 13/946,438 is a continuation of application No. 12/151,980, filed on May 9, 2008, granted, now 8,492,118, issued on Jul. 23, 2013.
Claims priority of provisional application 60/928,900, filed on May 11, 2007.
Prior Publication US 2023/0257437 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/09 (2006.01); C12N 15/62 (2006.01); G01N 33/569 (2006.01); A61K 38/00 (2006.01); C07K 16/18 (2006.01); C12P 21/00 (2006.01)
CPC C07K 14/5443 (2013.01) [A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); C07K 14/7051 (2013.01); C07K 14/7155 (2013.01); C07K 16/28 (2013.01); C12N 15/09 (2013.01); C12N 15/62 (2013.01); G01N 33/56977 (2013.01); A61K 38/00 (2013.01); C07K 16/18 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C07K 2319/75 (2013.01); C12P 21/00 (2013.01)] 17 Claims
 
1. A method of treatment for cancer or viral infection in a mammal in need thereof, the method comprising administering an effective amount of a soluble fusion protein complex comprising two soluble proteins, wherein the first soluble protein comprises:
(a) a fusion protein comprising a first biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide, or
(b) an IL-15 polypeptide; and
the second soluble protein comprises a fusion protein comprising:
(c) a second biologically active polypeptide covalently linked to (d) an interleukin-15 receptor alpha (IL-15Ra) polypeptide;
wherein the first and/or second biologically active polypeptides comprise cytokines, chemokines, growth factors or receptor binding domains thereof;
wherein the IL-15 domain of the first soluble protein binds to the IL-15Ra domain of the second soluble protein to form the soluble fusion protein complex; and
wherein the first biologically active polypeptide is different than an IL-15Ra polypeptide, and the second biologically active polypeptide is different than an IL-15 polypeptide.